Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on September 29, 2015. The report details a scientific presentation made on September 28, 2015, at the American Neurological Association Annual Meeting regarding the company's clinical trials.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements.
Material Changes
The material event reported is the presentation of clinical data by Dr. Eva Feldman, MD, PhD. The presentation included:
- Nine-month Phase II data for the NSI-566 trial in amyotrophic lateral sclerosis (ALS).
- Combined Phase I and Phase II data for the NSI-566 trial in ALS.
- Information regarding Human Cortical Neural Stem Cells in Alzheimer's Disease.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future financial performance, or a discussion of risks and contingencies beyond the context of the clinical data presentation. The report serves to disclose the dissemination of scientific results to the public.
Investor Verification Checklist
- Verify the specific clinical outcomes and statistical significance of the NSI-566 Phase II data presented in the attached slides (Exhibit 99.02).
- Review the press release (Exhibit 99.01) for any immediate implications on the company's development timeline.
- Confirm the status of the Alzheimer's Disease research mentioned in Exhibit 99.03.
- Check subsequent filings for any regulatory feedback or changes in trial design resulting from this presentation.